Assessment of early lung disease in young children with CF: A comparison between pressure-controlled and free-breathing chest computed tomography by Oudraad, M.C.J. (Merel C.J.) et al.
Pediatric Pulmonology. 2020;1–8. wileyonlinelibrary.com/journal/ppul | 1
Received: 16 March 2019 | Accepted: 11 February 2020
DOI: 10.1002/ppul.24702
OR I G I N A L AR T I C L E : C Y S T I C
F I B RO S I S— P ED I A T R I C & ADU L T
Assessment of early lung disease in young childrenwith CF: A
comparison between pressure‐controlled and free‐breathing
chest computed tomography
Merel C. J. Oudraad1 | Wieying Kuo2,3 | Tim Rosenow4,5 |
Eleni‐Rosalina Andrinopoulou6 | Stephen M. Stick7 | Harm A. W. M. Tiddens2,3
1Faculty of Medicine, University of Utrecht,
Utrecht, The Netherlands
2Department of Pediatric Pulmonology and
Allergology, Erasmus MC‐Sophia Children's
Hospital, Rotterdam, The Netherlands
3Department of Radiology and Nuclear
Medicine, Erasmus MC, Rotterdam, The
Netherlands
4School of Paediatrics and Child Health, The
University of Western Australia, Perth,
Australia
5Telethon Kids Institute, The University of
Western Australia, Perth, Australia
6Department of Biostatistics, Erasmus MC,
Rotterdam, The Netherlands
7Department of Respiratory and Sleep
Medicine, Princess Margaret Hospital for
Children, Perth, Australia
Correspondence
Harm A. W. M. Tiddens, Erasmus MC,




Background: Chest computed tomography (CT) in children with cystic fibrosis (CF) is
sensitive in detecting early airways disease. The pressure‐controlled CT‐protocol com-
bines a total lung capacity scan (TLC PC‐CT) with a near functional residual capacity scan
(FRC PC‐CT) under general anesthesia, while another CT‐protocol is acquired during free
breathing (FB‐CT) near functional residual capacity. The aim of this study was to evaluate
the sensitivity in detecting airways disease of both protocols in two cohorts.
Methods: Routine PC‐CTs (Princess Margaret Children's Hospital) and FB‐CTs
(Erasmus MC—Sophia Children's Hospital) were retrospectively collected from CF
children aged 2 to 6 years. Total airways disease (%disease), bronchiectasis (%Bx),
and low attenuation regions (%LAR) were scored on CTs using the Perth‐Rotterdam
annotated grid morphometric analysis‐CF method. The Wilcoxon signed‐rank test
was used for differences between TLC and FRC PC‐CTs and the Wilcoxon rank‐sum
test for differences between FRC PC‐CTs and FB‐CTs.
Results: Fifty patients with PC‐CTs (21 male, aged 2.5‐5.5 years) and 42 patients
with FB‐CTs (26 male, aged 2.3‐6.8 years) were included. %Disease was higher on
TLC PC‐CTs compared with FRC PC‐CTs (median 4.51 vs 2.49; P < .001). %Disease
and %Bx were not significantly different between TLC PC‐CTs and FB‐CTs (median
4.51% vs 3.75%; P = .143 and 0.52% vs 0.57%; P = .849). %Disease, %Bx, and %LAR
were not significantly different between FRC PC‐CTs and FB‐CTs (median 2.49% vs
3.75%; P = .055, 0.54% vs 0.57%; P = .797, and 2.49% vs 1.53%; P = .448).
Conclusions: Our data suggest that FRC PC‐CTs are less sensitive than TLC PC‐CTs and
that FB‐CTs have similar sensitivity to PC‐CTs in detecting lung disease. FB‐CTs seem to
be a viable alternative for PC‐CTs to track CF lung disease in young patients with CF.
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1 | INTRODUCTION
Cystic fibrosis (CF) lung disease starts in infancy; lung abnormalities
have been demonstrated on chest computed tomography (CT) in
1‐year‐old children.1,2 Timely detection of lung disease in young
children is considered important to initiate or change treatment with
the aim to prevent progression into irreversible lung damage even
though there are no well‐established therapies for this age category.
Chest CT is the current gold standard to detect airways disease,
including bronchiectasis, airway wall thickening, mucous plugging,
and low attenuation regions (LAR).3–6 The presence of bronchiectasis
is a highly relevant clinical finding; it negatively affects the quality of
life and increases the risk of respiratory tract exacerbations.7,8
Airway wall thickening and mucous plugs are both the result of lung
inflammation and have a prevalence of 85% and 79% in children with
CF, respectively.9 LAR are considered indirect visualizations of small
airway disease on CT, and are thought to represent a combination of
trapped air and hypoperfusion.7,10,11 For children of 6 years and
above standardization of lung volumes during CT acquisition has
been advocated when using objective and sensitive assessments of
airway dimensions to diagnose bronchiectasis, airway wall thickening,
and LAR.12–15 In these CF patients bronchiectasis, airway wall
thickening and mucous plugs are routinely assessed on inspiratory
CT,1 whereas LAR are assessed on expiratory CT.11 To optimize lung
volume for a CT‐scan it can be acquired in cooperative children
during a short voluntary breath hold after a deep inspiration near
total lung capacity (TLC) and after expiration near residual volume.
A lung function scientist trains the children with or without a
spirometer before the CT and supervises them during these breath
holds during CT acquisition. This method is described as the
technician‐guided chest CT method.16
In young, noncooperative children, chest CTs can be acquired
under general anesthesia using a pressure‐controlled CT‐protocol
(PC‐CT) to minimize movement artefacts and allow CT‐scanning at
inspiration and expiration.17 A low‐dose inspiratory PC‐CT is acquired
to evaluate airways disease after inflating the lungs close to TLC using
a transpulmonary pressure of 25 to 30 cm H2O. An ultra‐low‐dose
expiratory PC‐CT to evaluate LAR is acquired at a transpulmonary
pressure of 0 cm H2O, which results in a volume level close to
functional residual capacity (FRC).18 A disadvantage of PC‐CT,
however, is that it requires general anesthesia. Newer generations
of fast multislice CT‐scanners allow low‐dose chest CTs to be acquired
during free breathing (FB‐CT) with limited motion artefacts and
without the need for general anesthesia.16,19 With FB‐CT a single low
dose CT is acquired near FRC to evaluate both airways disease and
LAR. A disadvantage of the FB‐CT method compared with PC‐CT is
that the lung volume during acquisition is not controlled.16
Even though control of lung volume during CT is preferred,
structural lung disease can still be detected and scored on scans
without volume control. In school‐aged children the CF‐CT scores on
FRC‐CTs correlated well with those on TLC‐CTs.20 However, in
young children, the sensitivity of bronchiectasis detection on FRC
PC‐CT was found to be lower compared with a TLC PC‐CT using the
CF‐CT scoring system,21 likely due to the low prevalence of
bronchiectasis in this age group. Recently, a more sensitive scoring
method, the Perth‐Rotterdam Annotated Grid Morphometry
Analysis of Cystic Fibrosis (PRAGMA‐CF), has been developed for the
quantification of early lung disease in young children. To date, the
sensitivity of PRAGMA‐CF to detect airways disease on TLC PC‐CTs
has not been compared with FRC PC‐CTs or FRC FB‐CTs in young
children with CF.
The aim of this study is to evaluate the extent of airways disease
on low‐dose TLC PC‐CT to ultra‐low‐dose FRC PC‐CT and of ultra‐low‐
dose FRC PC‐CT to low‐dose FRC FB‐CT using PRAGMA‐CF in two
cohorts of young children monitored using the AREST‐CF program.
We hypothesized that TLC PC‐CT is more sensitive to detect
airways disease compared with FRC PC‐CT. Furthermore, we expect
FRC PC‐CT and FRC FB‐CT to be equally sensitive to track airways
disease and LAR.
2 | MATERIALS AND METHODS
2.1 | Study population
Routine annual or biennial CTs of patients with CF were retrospectively
collected; PC‐CTs from the Princess Margaret Children's Hospital, Perth,
Australia and FRC FB‐CTs from the Erasmus MC‐Sophia Children's
Hospital, Rotterdam, The Netherlands. Patients in Perth and Rotterdam
were both routinely followed according to the Australian Respiratory
Early Surveillance Team for Cystic Fibrosis (AREST‐CF) protocol.22
2.1.1 | Pressure‐controlled computed tomography
Inclusion criteria: diagnosis of CF, participation in AREST‐CF cohort
in Perth, age between 2 and 6 years and availability of a TLC PC‐CT
and FRC PC‐CT. All PC‐CTs before 2012 were obtained with a Philips
Brilliance 64 CT‐scanner (Phillips Healthcare, Jolimont, WA) and
from 2012 with a Siemens SOMATOM Definition Flash CT‐scanner
(Siemens Healthcare, Bayswater, Victoria, Australia). Detailed scan
parameters can be found in online supplementary material (Table S1).
All PC‐CT were acquired under general anesthesia.
2.1.2 | Free‐breathing computed tomography
Inclusion criteria: diagnosis of CF, participation in CF‐CT cohort in
Rotterdam, age between 2 and 6 years and availability of FRC FB‐CT
or technician‐guided FRC‐CT. Technician‐guided FRC‐CTs were
included in the FB‐CT group and will also be addressed as FB‐CT in
this paper, because technician‐guided FRC‐CTs are acquired near
FRC volume, similar to FB‐CTs.16,19 All CTs from Rotterdam were
obtained with SOMATOM Definition Flash CT‐scanner (Siemens
Healthcare, Forchheim, Germany). Detailed scan parameters can be
found in the Table S1. All FB‐CTs were acquired without sedation.
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2.2 | PRAGMA‐CF scoring
All CTs were anonymized and randomized before being assessed
using PRAGMA‐CF method. PRAGMA‐CF is a morphological grid‐
based assessment method for the quantification of airways disease in
young children with CF.23 Grid size is adjusted to the width of the
lung. In short, the following structural abnormalities are annotated
on axial CT‐slices according to a hierarchical system (highest to
lowest priority): bronchiectasis, mucous plugging, airway wall thick-
ening, atelectasis, or normal lung. For each of these components, the
volume is computed and expressed as a percentage (%) of the total
lung volume (ie, %bronchiectasis, %mucous plugging, %airway wall
thickening, %atelectasis, and %normal lung. In addition, %disease,
representative of total structural disease extent and incorporating all
CT changes related to airways disease, is computed as the sum of %
bronchiectasis, %mucous plugging, and %airway wall thickening. The
volume of atelectasis (%atelectasis) is subtracted from the total lung
volume before computing %disease score in all PC‐CTs, because at-
electasis on PC‐CT can be the consequence of general anesthesia in
children and is not always related to CF lung disease.18 For FB‐CT,
volume of atelectasis was also subtracted from total lung volume for
consistency, even though these CTs were acquired without general
anesthesia or sedation. %Bronchiectasis, %mucous plugging, and %
airway wall thickening were scored on TLC and FRC PC‐CTs and on
FRC FB‐CTs. LAR was scored on FRC PC‐CTs and FRC FB‐CTs and
expressed as a percentage of total lung volume (%LAR). All scans
were scored by a single observer (MCJO), a medical master student
certified in CF‐CT scoring and PRAGMA‐CF scoring. To determine
intra‐observer reliability a subset of 30 CTs was re‐randomized and
rescored after more than 1 month.
2.3 | Statistical analysis
Patient characteristics are computed using descriptive statistics.
PRAGMA‐CF scores are computed as median (range). The Wilcoxon
rank‐sum test was conducted to compare continuous patient char-
acteristics and to compare PRAGMA‐CF scores. Fisher's exact test
was used to compare categorical patient characteristics. The Wil-
coxon signed‐rank test was used to compare PRAGMA‐CF scores in
paired data (TLC PC‐CT with FRC PC‐CT). For comparisons with the
subscore %bronchiectasis only patients with bronchiectasis were
included, being considered a group with more severe airways disease.
%Disease scores were divided in high (above median) and low (below
median) score groups to investigate the relationship between %at-
electasis and %disease. Intraobserver reliability was assessed using
the intraclass correlation coefficient (ICC). Because no universally
applicable standards are available for reliability, an ICC between
0.4 and 0.6 was considered moderate, between 0.6 and 0.8 good, and
greater than 0.8 excellent.23 The relationship between PRAGMA‐CF
scores and age was investigated using linear regression analysis. For
%bronchiectasis, the logarithmic scale was used because the as-
sumption that the variance of the error terms is constant
(homoscedasticity) was not satisfied in the original scale. This re-
gression was repeated with the exclusion of the second FRC FB‐CT
of patients with follow‐up CTs to investigate if the relationship still
existed. No correction was applied to account for multiple testing.
A P value of < .05 was selected as significant.
3 | RESULTS
3.1 | Study population
A total of 170 patients with AREST‐CF having PC‐CTs met the in-
clusion criteria. About 50 out of 170 patients with each a TLC PC‐CT
and FRC PC‐CT were randomly selected and included in this study. A
total of 37 patients with CF‐CT met the inclusion criteria and were
included in this study, of which four patients had two routine CTs
(one baseline FB‐CT and one follow‐up technician‐guided CT) and
one patient had two FB‐CTs. Hence, a total of 42 CTs were included
in the FRC FB‐CT group consisting of 29 FRC FB‐CTs and
13 technician‐guided FRC‐CTs. Patient characteristics and their
comparisons can be found in Table 1.
Bronchiectasis was detected in up to 43% in the two CT‐protocol
groups (see Table 1). There was no significant difference in age be-
tween the patients with bronchiectasis and patients without
bronchiectasis observed (median [range] 4.31 years [2.28‐6.77] and
4.17 years [2.70‐6.54], respectively, P = .357). Because of the high
prevalence of patients without bronchiectasis (%bronchiectasis = 0%)
we only compared %bronchiectasis between the two cohorts for
those patients who had a subscore above 0%. As can be seen in
Table 1, this resulted in inclusion of 14 patients in the TLC PC‐CT
group, nine patients in the FRC PC‐CT group and 18 patients in the
FRC PC‐CT group.
Atelectasis was scored in 64% of the TLC PC‐CT, 44% of the
FRC PC‐CT, and 33% of the FRC FB‐CT group (Table 1). The
median value for %disease subscore for the two CT‐protocol
groups combined was 3.67%. For further analysis, we considered a
value for %disease higher than 3.67% as the high disease group,
whereas %disease below 3.67% was considered the low disease
group. %Atelectasis was higher in the FRC PC‐CT high disease
group compared with the FRC PC‐CT low disease group (P = .001)
(Table S2).
3.2 | PRAGMA‐CF scoring: TLC PC‐CT vs FRC
PC‐CT vs FRC FB‐CT
Figure 1 shows the boxplots of %bronchiectasis, %disease, %airway
wall thickening, and %LAR scored for the PC‐CT and FB‐CT groups.
There was no significant difference in %bronchiectasis between TLC
PC‐CT compared with FRC PC‐CT (median [range] 0.52 [0.12‐8.09]
and 0.54 [0.12‐2.28], P = .075). %Disease was higher on TLC PC‐CT
compared with FRC PC‐CT (median [range] 4.51 [1.39‐12.62] and
2.49 [0.41‐10.47], respectively, P < .001).
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Correlations comparisons of PRAGMA‐CF scores between TLC
PC‐CT, FRC PC‐CT, and FRC FB‐CT are shown in Table 2.
3.3 | Intraobserver reliability
The ICC (95% CI) for %bronchiectasis, %disease, and %LAR were
0.83 (0.75‐0.89), 0.86 (0.79‐0.91), and 0.99 (0.98‐1.00), respectively.
3.3.1 | %Bronchiectasis and %disease vs age
To evaluate the sensitivity of PC‐CT and FB‐CT groups to detect
structural lung abnormalities, we investigated the associations be-
tween the logarithmic scale of %bronchiectasis and age and between
%disease and age for both cohorts (Figure 2). The logarithmic scale of
%bronchiectasis did not show a significant increase with age in pa-
tients with TLC PC‐CTs (β = .091, SE = 0.192, P = .758), FRC PC‐CTs
(β = .279, SE = 0.163, P = .468), and FRC FB‐CTs (β = .410, SE = 0.126,
P = .091). %Disease increased significantly with age for FRC PC‐CTs
(β = .353, SE = 0.313, P = .012) and FRC FB‐CTs (β = .362, SE = 0.438,
P = .018) (Figure 2). When excluding the second FRC FB‐CT of the
five patients with follow‐up CTs, the increase of the logarithmic scale
of %bronchiectasis with age remains insignificant (β = .330, SE =
0.152, P = .229), while %disease continued to show a trend towards
progression (β = .300, SE = 0.470, P = .071).
4 | DISCUSSION
This is the first study in young children investigating PRAGMA‐CF
scores of airways disease on CTs acquired using a pressure‐
controlled protocol and on CTs acquired using a free‐breathing
CT‐protocol in two cohorts. Our cross‐sectional analysis showed that
airways disease can be detected with both CT‐protocols using
PRAGMA‐CF scoring.
An important observation is that there is no significant differ-
ence in the detection of %bronchiectasis on TLC PC‐CTs compared to
FRC PC‐CTs or to FRC FB‐CTs. This is in line with a previous study in
older children with CF, which shows that CF‐CT scores of end‐
expiratory CTs and end‐inspiratory CTs match well.20 However, a
study by Mott et al21 in 10 young CF patients below the age of
5 years showed a significant lower number of bronchiectatic airways
at FRC level measuring airway artery dimensions on sequential axial
CT‐slices. Like in other studies, we observed a prevalence of
bronchiectasis between 18% and 43%. However, the extend of
bronchiectasis in CF at this young age was low for both CT‐protocols.
This discrepancy between the findings of the study by Mott et al21
and our current study is likely to be the result of the use of a more
sensitive volumetric CT protocol for our image analysis.
In contrast to bronchiectasis, %disease was significantly higher
on TLC PC‐CTs compared with FRC PC‐CTs. This can be explained by
the fact that on TLC PC‐CTs airways are larger relative to the FRC
PC‐CTs, allowing the evaluation of almost double the amount of
TABLE 1 Patient characteristics and
prevalence of structural abnormalities
scored on FRC FB‐CT, TLC PC‐CT, and
FRC‐CT
TLC/FRC PC‐CT FRC FB‐CT P value
Patient characteristics
Total n 50 42
Male total n (%) 21 (42) 26 (62) .06
Age, ya 4.25 (2.51‐5.48) 4.12 (2.28‐6.77) 1.00
Pancreatic insufficiency n (%) 40 (80) 39 (93) .13
Homozygous deltaF508 n (%)b 23 (46) 28 (67) .06
Heterozygous deltaF508 n (%)b 26 (52) 14 (33) .09
Two other mutations n (%)b 1 (2) 0 (0)
Pseudomonas n (%)c 13 (26) 10 (24) 1.00
TLC PC‐CT FRC PC‐CT FRC FB‐CT
Prevalence structural abnormalities
Bronchiectasis n (%) 14 (28) 9 (18) 18 (43)
Airway wall thickening n (%) 50 (100) 50 (100) 42 (100)
Mucous plugging n (%) 4 (8) 6 (12) 14 (33)
Atelectasis n (%) 32 (64) 22 (44) 14 (33)
Low attenuation region n (%) 43 (86) 31 (74)
Note: Data are presented as a number of patients with median percentage between brackets unless
otherwise specified.
Abbreviations: FRC FB‐CT, functional residual capacity free‐breathing computed tomography; FRC
PC‐CT, functional residual capacity expiratory pressure‐controlled computed tomography; TLC PC‐
CT, total lung capacity inspiratory pressure‐controlled computed tomography.
aAge is presented as median (range).
bGenotypes of patients were divided in patients with a homozygous deltaF508 genotype (deltaF508/
deltaF508), patients with a heterozygous deltaF508 genotype (deltaF508/other mutation), and
patients with two other mutation genotypes.
cPseudomonas detected in BAL at the time of the scans or in the past.
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airways, including diseased airways.15,24 Another explanation is that
for TLC PC‐CTs about double the radiation dose was used compared
with an FRC PC‐CTs as the latter is only used routinely for the de-
tection of LAR.25 In general, a lower radiation dose results in lower
image quality and therefore reduced sensitivity to detect airways.24
Similarly, the radiation dose for FRC FB‐CTs is higher compared with
FRC PC‐CTs as FRC FB‐CTs are used both to assess airway disease
as well as LAR. This is in line with the observation that %disease on
FRC FB‐CTs was between that of the TLC PC‐CTs and FRC PC‐CTs.
Similarly, %airway wall thickening on FRC FB‐CTs was between that
of TLC PC‐CTs and FRC PC‐CTs. However, we must be cautious in
making comparisons with the two cohorts. Interestingly, %mucous
plugging on FRC PC‐CTs was observed in a significantly higher
percentage than on TLC PC‐CTs. This can be explained by the in-
creased visibility of occluded airways at the FRC level due to the
combination of folding of the thickened mucosa and mucus in the
airway, filling up the space between the mucosal folds and/or lu-
men.26,27 These observations support the use of %disease on FRC
FB‐CTs as an alternative for %disease on TLC PC‐CTs and FRC
PC‐CTs when using a similar radiation dose for FRC FB‐CTs as used
for TLC PC‐CTs.25
For %LAR there were no significant differences between FRC
FB‐CTs and FRC PC‐CTs. Some more variability in lung volume could
be expected in FRC FB‐CTS compared with the PC‐CTs which could
have reduced the sensitivity to detect LAR on FRC FB‐CTs.19 How-
ever, the higher radiation dose of FRC FB‐CTs compared with FRC
F IGURE 1 Boxplots of %bronchiectasis (A), %disease (B), %airway wall thickening (C), and %LAR (D) scored on inspiratory pressure‐
controlled CTs (TLC PC‐CTs), expiratory pressure‐controlled CTs (FRC PC‐CTs), and free‐breathing CTs (FRC FB‐CTs), The boxes display the
interquartile range of each PRAGMA‐CF outcome and contain 50% of the cases. The black line in the middle of the boxes represents the median
score and whiskers go out to the smallest and largest scores. “o” indicates outliers (scores that are quite different from the remainder of the
scores) and “*” indicates extreme outliers. Six extreme outliers of %LAR and one extreme outlier of %bronchiectasis could not be displayed in
the figures. “#” indicates a significantly higher score of %disease for TLC PC‐CT compared with FRC PC‐CT. CT, computed tomography; FRC,
functional residual capacity; LAR, low attenuation region; PRAGMA‐CF, Perth‐Rotterdam annotated grid morphometric analysis for cystic
fibrosis; TLC, total lung capacity
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PC‐CTs is likely to improve the sensitivity of FRC FB‐CTs to
detect LAR.
As expected atelectasis was observed in around half of the
patients with PC‐CTs.18 Interestingly, atelectasis was also observed
on FRC FB‐CTs in around one‐third of the patients, showing that
children with CF are prone to develop atelectasis even without
general anesthesia. This is likely to be related to CF lung disease in
combination with the supine position during the execution of the
CT‐scan. To our knowledge, the prevalence of atelectasis on FRC FB‐
CTs in young children with CF has not been described before in the
literature. This observation supports the clinical relevance of in-
cluding quantification of atelectasis using the PRAGMA‐CF score on
CTs as a marker of CF lung disease.
In our cross‐sectional study, %disease increased significantly
with age for both patient groups. This supports that progression of
CF lung disease between the ages of 2 and 6 could possibly be
monitored using %disease for the TLC PC‐CT as well as for the FRC
FB‐CT protocol. %Bronchiectasis did not show a significant increase
with age for the two groups, which can be explained by the low
extend of true bronchiectasis in the lungs of young children with CF.
Clearly, longitudinal studies with pre‐school aged patients providing
multiple CTs over time are needed to compare the sensitivity of
FB‐CT and PC‐CT to monitor the progression of CF lung disease
using the PRAGMA‐CF scoring method.
Both the PC‐CT and FB‐CT protocol have advantages and
disadvantages for monitoring CF lung disease (Table S3). The most
important disadvantage of PC‐CT over FB‐CT is that it requires
general anesthesia. However, it must be noted that in multiple CF
centers the PC‐CT under general anesthesia is combined with a
diagnostic bronchoscopy.28 Another disadvantage of PC‐CT is that
there is a higher risk for the development of atelectasis especially
in those patients with more severe lung disease. The observed
atelectasis related to the PC‐CT underlines the importance of using
a recruitment protocol at the end of the anesthesia procedure to
reverse procedure‐related atelectasis.18 In addition, post-
anesthesia recruitment exercises under the supervision of a phy-
siotherapist can be considered to further reduce this risk. Another
disadvantage of PC‐CT is that the total radiation dose needed is
somewhat higher relative to FB‐CT, as the latter requires only a
single low dose volumetric scan at FRC level in contrast to PC‐CT,
which includes a low‐dose volumetric scan at TLC and an ultra‐low
dose at FRC. However, it should be noted that the total radiation
TABLE 2 PRAGMA‐CF outcomes %bronchiectasis, %disease, %airway wall thickening, %mucous plugging, and %LAR scored on TLC PC‐CTs,
FRC PC‐CTs, and FRC FB‐CTs
PRAGMA‐CF scores TLC PC‐CT FRC PC‐CT FRC FB‐CT P value* P value** P value***
%Bronchiectasis 0.52 (0.12‐8.09) 0.54 (0.12‐2.28) 0.57 (0.07‐4.27) .075 .849 .797
%Disease 4.51 (1.39‐12.62) 2.49 (0.41‐10.47) 3.75 (0.08‐13.11) <.001 .143 .055
%Airway wall thickening 4.32 (0.89‐8.87) 3.18 (0.08‐7.60) 3.65 (0.42‐7.01) .026 .003 .188
%Mucous plugging 0.00 (0.00‐1.33) 0.00 (0.00‐2.10) 0.00 (0.00‐7.94) .047 .002 .018
%Atelectasis 0.29 (0.00‐6.57) 0.00 (0.00‐6.74) 0.00 (0.00‐2.88) .074 .001 .149
%LAR 2.48 (0.00‐51.52) 1.53 (0.00‐35.36) .143
Note: Significance (P values) of comparison of PRAGMA‐CF scores between FRC FB‐CTs vs TLC PC‐CTs and FRC FB‐CTs vs FRC PC‐CT are also displayed.
Data are presented as median (range) unless otherwise specified.
Abbreviations: FRC FB‐CT, functional residual capacity free‐breathing computed tomography; FRC PC‐CT, functional residual capacity expiratory
pressure‐controlled computed tomography; LAR, low attenuation region; PRAGMA‐CF, Perth‐Rotterdam annotated grid morphometric analysis for cystic
fibrosis; TLC PC‐CT, total lung capacity inspiratory pressure‐controlled computed tomography.
*Comparison of PRAGMA‐CF scores between TLC PC‐CT and FRC PC‐CT.
**Comparison of PRAGMA‐CF scores between TLC PC‐CT and FRC FB‐CT.
***Comparison of PRAGMA‐CF scores between FRC PC‐CT and FRC FB‐CT.
F IGURE 2 PRAGMA‐CF outcome %disease plotted against age of
all patients for inspiratory pressure‐controlled CTs (TLC PC‐CTs,
open circles), expiratory pressure‐controlled CTs (FRC PC‐CTs, closed
circles), and free‐breathing CTs (FRC FB‐CTs, stars), The line shows
the correlation between %disease and age for all patient groups. The
regression equation is as follows: %Disease = 0.64 + 0.82 Age. A
common slope is shown as there was no difference in slope between
FB‐CT vs age and PC‐CT vs age. CT, computed tomography; FRC,
functional residual capacity; PRAGMA‐CF, Perth‐Rotterdam
annotated grid morphometric analysis for cystic fibrosis; TLC, total
lung capacity
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dose needed for both protocols is low and the risks related to the
protocols are considered low.29 A clear advantage of PC‐CT over
FB‐CT is better standardization of lung volume for especially the
inspiratory PC‐CT at the TLC level. Previous studies have estab-
lished the importance of standardization of volume levels during
chest CT.12–14,21 It has been shown that the airway to artery ratio
to diagnose bronchiectasis is dependent on lung volume.30 How-
ever, bronchiectatic and thickened airways can also be diagnosed
at the FRC level.20 The expiratory scan for the PC‐CT protocol will
be at the FRC level when sufficient time is taking to let the lung
deflate. The FB‐CT will be at the FRC level plus minus the tidal
volume. However, when a child is upset the volume level can be
more variable. Finally, FB‐CTs have a higher risk of motion artifacts
compared with PC‐CTs due to the child's tidal breathing. However,
in our series, all FB‐CTs were of good quality without major
movement artifacts. This risk for movement artifacts can be re-
duced by training cooperative children before the scan in a mock
scanner and by using modern fast CT‐scanners and a high‐pitch
spiral CT‐protocol.19
There are some important limitations to this study. The most
important one is that the FB‐CTs and PC‐CTs were executed in two
different patient cohorts. The ideal protocol would be to do a FB‐CT
and PC‐CT protocol within a short time frame in the same patient.
Unfortunately, such a study has ethical limitations, as it would expose
the patients to a higher dose of radiation. An alternative is alter-
nating within the same cohort biennial PC‐CT with biennial FB‐CT
but such a study takes 5 to 6 years to complete. However, the two
cohorts of these young CF children from Rotterdam and Perth are
similar in their key characteristics, such as age, gender, CF genotype,
pancreatic insufficiency, and Pseudomonas status. Furthermore, both
centers have been collaborating closely together since 2004 and
Rotterdam has a structural follow‐up protocol similar to the AREST‐
CF protocol for 6 years with the exception of the CT‐protocol.
Clearly, it is well possible that demographical differences or differ-
ences in clinical management could have created a systemic bias
between both cohorts. In addition, different CT‐scanners and CT‐
scan protocols were used from two different centers. However, it is
well recognized that scoring techniques are less sensitive to differ-
ences in CT‐protocols.
Another important limitation is that only a relative small sample
size was studied, which reduced the sensitivity to find differences.
This might have especially affected the comparison for bronchiectasis
which has a relatively low prevalence and extend in these young
patients with CF having early lung disease. However, %disease and
low attenuation regions could be easily and reliably scored for both
CT protocols. Given the above considerations, no strong conclusions
can be made and this manuscript serves as a descriptive analysis.
Future research, that could benefit from these descriptive results,
should be performed for a more reliable comparison.
This cross‐sectional study suggests that FRC PC‐CTs have
comparable sensitivity to TLC PC‐CT in terms of detecting airways
disease in young children with CF. Furthermore, FRC FB‐CTs can be
used to detect CF lung disease.
Our data suggest that the free‐breathing method is a general
anesthesia‐free alternative to track CF lung disease for the pressure‐
controlled method when a fast multislice CT‐scanner is available. Overall,
PC‐CT is the preferred technique when it is combined with a diagnostic
bronchoscopy or when standardized sensitive airway to artery mea-
surements are needed. When this is not the case FB‐CT is the preferred
technique as it reduces the burden for the patient and costs. Currently,
running clinical trials in larger study populations that include both FRC
FB‐CTs and PC‐CTs will generate more robust data on the sensitivity of
both techniques for monitoring progression in CF lung disease.
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